Liangjiang New Area in southwestern Chongqing municipality has an advantage in medical product manufacturing, according to area officials.
Since the beginning of the battle for novel coronavirus prevention and control, Liangjiang's medical companies has worked at full capacity to provide medical supplies, they said.
Chongqing Huapont Pharmaceutical Co restarted production lines related to anti-virus medicines on Jan 26. Currently the production line of methylprednisolone sodium succinate for injections -- one of the key medicines to treat virus infections -- is being operated at full load and can produce 60,000 battles of injections per day.
Meanwhile, Huapont has increased the production of moxifloxacin hydrochloride tablets, which can treat the upper and lower respiratory infection. All the medicines will be transported to worst-hit areas in Central China's Hubei province, officials said.
Elsewhere, Liangjiang also has Master Kong at Tingyi Cayman Island Holding Corp's largest noodle production factory. Relying on Chongqing's traffic and market influence advantages, the factory’s sales volume occupies 45 percent of the corporation's southwestern Chinese market.
To meet the needs of daily food supplies, Master Kong's Chongqing factory has recovered 75 percent of capacity, which can produce 2 million instant noodles selling to Hubei.
Statistics showed that by Feb 2, Liangjiang has 10 key companies which had restarted manufacturing, involving 10,000 employees and a daily average output value of 65 million yuan ($9.28 million). From Jan 24 to Feb 3, Liangjiang produced 631.95 million yuan worth of products.